Aquestive Therapeutics (NASDAQ:AQST) Reports Q2 2026 Financials Amidst Anaphylm Progress
- Aquestive Therapeutics (NASDAQ:AQST) reported a Q2 2026 EPS miss at -$0.18 but exceeded revenue expectations with $13.82 million.
- The biopharmaceutical company is advancing its Anaphylm sublingual film, with NDA resubmission to the FDA expected in Q3 2026.
- Despite a negative P/E ratio of -6.78, Aquestive Therapeutics demonstrates strong short-term financial stability with a current ratio of 7.19.
Aquestive Therapeutics (NASDAQ:AQST) is a biopharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs. It operates within the competitive pharmaceutical industry. The company leverages its proprietary PharmFilm® technology, an advanced drug delivery platform that utilizes a small, dissolvable oral film for drug administration, offering an alternative to traditional injections or pills.
On August 11, 2026, Aquestive Therapeutics released its second-quarter financial results. The biotech firm posted an earnings per share (EPS) of -$0.18. This EPS figure missed the analyst consensus estimate of -$0.11 and represented a wider loss than the -$0.14 per share reported in the same quarter a year ago, resulting in an earnings surprise of -80.00%.
Despite the earnings miss, Aquestive Therapeutics announced quarterly revenue of $13.82 million. This top-line result surpassed the estimated $11.42 million. As highlighted by Zacks, this revenue figure marks an increase from the $10 million reported a year prior and exceeded the consensus estimate by 12.76%, indicating consistent financial performance.
As noted by GlobeNewswire, Aquestive Therapeutics provided a business update alongside its financials. The pharmaceutical company completed key studies for its Anaphylm sublingual film, a promising drug candidate for severe allergic reactions. It remains on track to resubmit its New Drug Application (NDA) to the FDA in the third quarter of 2026, underscoring its continued investment in its drug development pipeline.
The company's financial health presents mixed signals. It currently holds a negative price-to-earnings (P/E) ratio of -6.78, indicating it is not yet profitable. However, its current ratio, a key liquidity metric measuring short-term financial stability, stands at a strong 7.19, suggesting robust capability to cover its immediate liabilities.